Health Press Release – Newsletter for March 17, 2011Thursday, March 17, 2011
ANN ARBOR, Michigan and LONDON, March 16, 2011 – NextGen Group plc (AIM:NGG) is pleased to announce that its
subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement
and qualification, has launched its first multiple protein (multiplex) assay,
plasmadiscovery41, for oncology biomarker discovery and qualification. The
assay simultaneously measures 41 human plasma proteins that are thought to
have … Read more : NextGen Sciences Launches Multiple Protein Plasma Oncology Biomarker Assay.
MADRID and OEIRAS, Portugal, March 16, 2011 – Digna Biotech and Biotecnol (The Consortium) announced today that the
Spanish Regulatory Medicine Agency has authorized the start of a Phase I
Clinical Trial in healthy volunteers for Cardiotrophin-I (CT-I). The study
will be conducted in Hospital Universitario Puerta de Hierro de Majadahonda
in Madrid and Cl??nica Universidad de Navarra …. Source : Cardiotrophin I to Start Phase I Clinical Studies.
The Additional Funds Will Enable the Company to Expand its Therapeutic Research Activities
STRASBOURG, France, March 16, 2011 – Polyplus-transfection SA, which specializes in the development
of innovative solutions for the delivery of nucleic acids in research and
therapeutics, announces the completion of a funding round in which it raised
EUR 2.5 million. This new round brings in …. Original source : Polyplus-Transfection Raises EUR 2.5 Million in Latest Funding Round.
Finesse Solutions Introduces New T700 cGMP Upstream Processing Platform Featuring G3 Hardware and Fully Integrated Single-Use Sensors
SAN JOSE, California, March 16, 2011 – Finesse Solutions, LLC, San Jose, CA, a manufacturer of measurement and
control solutions for life sciences process applications, announced the
release of the T700(TM) upstream processing platform for single-use
bioreactors ranging from 25L to 2,000L in size. The T700 family of turn-key
control systems is designed to the highest performance and … Read more »».
Dutch Firm Launches World’s First Diagnostic Chip That Combines DNA Technologies to Rapidly Classify AML Patients
ROTTERDAM, The Netherlands, March 16, 2011 – Each year over eight million people die of cancer worldwide. Patients'
chances of survival vary widely: depending on the type of cancer involved,
the stage at which it is diagnosed and the speed with which appropriate
treatment is launched. Skyline Diagnostics B.V., a Dutch firm associated with
the Erasmus Medical Center …. Original article : Dutch Firm Launches World's First Diagnostic Chip That Combines DNA Technologies to Rapidly Classify AML Patients.